Ken Fisher Crinetics Pharmaceuticals, Inc. Transaction History
Fisher Asset Management, LLC
- $247 Billion
- Q4 2024
A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 559,287 shares of CRNX stock, worth $19.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
559,287
Previous 482,099
16.01%
Holding current value
$19.9 Million
Previous $24.6 Million
16.13%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding CRNX
# of Institutions
252Shares Held
89.2MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$323 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$247 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$221 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$218 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$192 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.91B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...